Nereid Therapeutics will advance research by Clifford Brangwynne of Princeton University following its launch with a $50m series A round from Apple Tree Partners.
Nereid Therapeutics, a US-based developer of treatments for cancer and neurodegenerative diseases based on research at Princeton University, was launched this week by venture firm Apple Tree Partners with $50m in series A capital.
Nereid will develop therapies targeting biomolecular condensates, a specialised subunit of the cell, using research by scientific founder Clifford Brangwynne, a professor in the Department of Chemical and Biological Engineering at Princeton University and an investigator at the Howard Hughes Medical Institute.
Brangwynne’s work…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
